<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81933">
  <stage>Registered</stage>
  <submitdate>27/03/2007</submitdate>
  <approvaldate>2/04/2007</approvaldate>
  <actrnumber>ACTRN12607000190404</actrnumber>
  <trial_identification>
    <studytitle>Extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diease</studytitle>
    <scientifictitle>A multicentre phase II trial of extended treatment with rituximab to assess complete remission rate in patients with B-cell post-transplant lymphoproliferative diease</scientifictitle>
    <utrn />
    <trialacronym>SLPT/01</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Post solid organ transplant lymphoproliferative disease</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment with 4 courses, one per week during 4 weeks, of intravenous Rituximab at a dose of 375 mg/m2  (standard doses). Patients who progressed were excluded from the study. Patients in complete remission after 4 courses were followed without further treatment. Participants in complete remission after 4 courses were followed up every 3 monts  during 2 years or until progression. Patients with partial response received another 4 weekly courses of rituximab at the same doses. Participants in complete remission after 8 courses were followed up every 3 monts during 2 years or until progression</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Complete remission rate</outcome>
      <timepoint>8 weeks after the end of the treatment (with CT scan).  If there were clinical data suggesting progression, patients could be evaluated at 4 weeks after the end of treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate</outcome>
      <timepoint>At 8 weeks after the end of treatment. If there were clinical data suggesting progression patients could be evaluated at 4 weeks after the end of treatment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival and progression-free survival at 2 years after the end of treatment</outcome>
      <timepoint>At 2 years after the end of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Signed informed consent, untreated B-cell lymphoproliferative disease, CD20 expression.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Central nervous system disease, serious concomitant diseases.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/11/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Alberto Fernández de Sevilla on behalf of the Catalan Institute of Oncology</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>GELTAMO: Spanish Group of Lymphoma</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Not randomized trial of treatment with standard doses of rituximab for untreated B-cell lymphoproliferative disease. Treatment regimen was adapted to early response, patients received 4 to 8 courses of rituximab.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ciutat Sanitaria i Universitaria de Bellvitge</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/04/2002</ethicapprovaldate>
      <hrec>93/02</hrec>
      <ethicsubmitdate />
      <ethiccountry>Spain</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eva González Barca</name>
      <address>Av. Gran Vía s/n Km 2,7
L'Hospitalet de LLobregat
08907 Barcelona</address>
      <phone>+34 93 2607750</phone>
      <fax>+34 93 2607797</fax>
      <email>e.gonzalez@iconcologia.net</email>
      <country>Spain</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Eva González Barca</name>
      <address>Av. Gran Vía s/n Km 2,7
L'Hospitalet de LLobregat
08907 Barcelona</address>
      <phone>+34 93 2607750</phone>
      <fax>+34 93 2607797</fax>
      <email>e.gonzalez@iconcologia.net</email>
      <country>Spain</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>